Adaptive deep brain stimulation (aDBS) controlled by local field potential oscillations

Abstract

Despite their proven efficacy in treating neurological disorders, especially Parkinson's disease, deep brain stimulation (DBS) systems could be further optimized to maximize treatment benefits. In particular, because current open-loop DBS strategies based on fixed stimulation settings leave the typical parkinsonian motor fluctuations and rapid symptom variations partly uncontrolled, research has for several years focused on developing novel “closed-loop” or “adaptive” DBS (aDBS) systems. aDBS consists of a simple closed-loop model designed to measure and analyze a control variable reflecting the patient's clinical condition to elaborate new stimulation settings and send them to an “intelligent” implanted stimulator. The major problem in developing an aDBS system is choosing the ideal control variable for feedback. Here we review current evidence on the advantages of neurosignal-controlled aDBS that uses local field potentials (LFPs) as a control variable, and describe the technology already available to create new aDBS systems, and the potential benefits of aDBS for patients with Parkinson's disease.

Introduction

Ample evidence obtained over the past decade shows that subthalamic DBS induces major clinical benefits in patients with advanced Parkinson's disease, with a persisting improvement in off-related motor symptoms ranging between 30% and 55% at 5-years evaluation together with a general improvement in rest tremor, rigidity, gait, and akinesia (Krack et al., 2003). The time spent with dyskinesias diminishes by 50% (Deuschl et al., 2006), and levodopa-induced dyskinesias diminish in severity by almost 70% (Kleiner-Fisman et al., 2006). Despite these benefits, and even though DBS brings about an overall improvement in parkinsonian patients' quality of life, DBS leaves the clinical fluctuations typically seen in advanced Parkinson's disease partly uncontrolled.

Several adverse motor symptoms induced by STN-DBS can be reversed by reprogramming stimulation parameters (Bronstein et al., 2011, Yu and Neimat, 2008, Frankemolle et al., 2010). For instance, very early reports showed that stimulation-induced hemiballism can be reversed by decreasing stimulation voltage (Limousin et al., 1996, Limousin et al., 1998). Motor side effects including dyskinesia can be reversed in 19% of patients by reprogramming DBS parameters (Hamani et al., 2005). STN-DBS can worsen speech and gait, but again symptoms may be improved by changing stimulation settings (Bronstein et al., 2011). These observations highlight the importance of reprogramming DBS parameters to optimize therapy. At present, however, DBS parameters can be changed only during follow-up visits without controlling clinical fluctuations and rapid variations in symptoms. Follow-up studies also showed that long-term DBS outcomes improve if the frequency of follow-up visits and DBS parameter setup increases (Moro et al., 2006).

Optimizing DBS therapy to control fluctuations and adverse effects means fine tuning DBS parameters (including frequency, amplitude, pulse width, and waveform) in a short time window. A possible solution would be an “intelligent” DBS system, able to change stimulation parameters when detecting symptom fluctuations and adverse effects as well as more subtle pathophysiological changes, without patients waiting until the next clinic visit for reprogramming (Burgess et al., 2010, Liu et al., 2011, Marceglia et al., 2007, Priori et al., 2005a, Priori et al., 2005b, Rosin et al., 2011, Santaniello et al., 2011, Winestone et al., 2012). This strategy is known as “closed-loop” or “adaptive” DBS (aDBS, Fig. 1). Closed-loop strategies have already been effectively applied in other neurological disorders, such as epilepsy, and closed-loop neuromodulatory systems for epilepsy are in clinical trials (Fridley et al., 2012, Marzullo et al., 2010, Stanslaski et al., 2012).

Here we examine the problem of choosing a neurosignal suitable as a control variable for aDBS, we review the technology already available to create new aDBS systems, and we suggest how new aDBS systems might benefit patients with Parkinson's disease.